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Parkinson's disease (PD) is one of the major degenerative disorders, affecting 2% of the population over 65 years and up to 4% in people over 85 years 1 . In Brazil, statistics show that the incidence of PD amounts to 150/200 cases per 100,000 inhabitants 2 . Most cases of PD are idiopathic 3 . However, in approximately 5%-10% of the cases, there is a genetic component with both dominant and recessive inheritance patterns 3 . The chromosomal loci linked to the familial forms of PD are termed PARK1-13. These loci include six autosomal dominant genes [PARK 1or PARK 4 (alpha synuclein -SNCA), PARK 3 (Lewy bodies), PARK 5 (ubiquitin carboxyl-terminal esterase L1 -UCHL1), PARK 8 (leucine-rich repeat kinase 2 -LRRK2) and PARK13 (HTRA serine peptidase 2 -HTRA2)], 4 recessives genes [PARK 2 (parkin -PRKN), PARK 6 (PTEN-induced putative kinase 1 -PINK1), PARK 7 (oncogene DJ1), PARK 9 (ATPase type 13A2 -ATP13A2)] and PARK11 (GIGYF2 -Grb10 Interacting GYF Protein-2),one gene linked to X chromosome (PARK12) and a form with unknown inheritance pattern (PARK10) 4, 5, 6 . Mutations identified in five major genes were related with genetic etiology of familial PD, such as a-synuclein, which mediates autosomal dominant forms of the disease 4 . The SNCA gene, located on human chromosome 4q21.3-q22, has 7 exons and encodes the a-synuclein protein of 140 amino acids, which is divided into three regions: N-terminal a-helical region (where mutations occur in the event of PD); central region (hydrophobic NAC sequence, known as non β-amyloid component), responsible for the formation of fibrils that cause toxicity; and the acidic C-terminal region 5 . The analysis of the sequence of exon 4 revealed that a single change of G →A (Guanine→Adenine) in the position 209 of the nucleotide chain causes the amino acid alanine to be replaced by the amino acid threonine at position 53 of the a-synucleinprotein 6 . The a-synuclein protein is the major protein component of intracellular neuron deposits observed in PD 7 . Although the function and the underlying dysregulation of SNCA mechanisms are not fully understood, the formation and expression of oligomers of this protein play a critical role in the development of the disease 8 . This wildtype a-synuclein protein is the major component of LB, in both familial and sporadic PD, which highlights the role of the SNCA gene variant in all presentations of the disease 9 . Functionally, relevant genetic variants in and near the SNCA gene are risk factors for sporadic PD (SPD). For example, the A53T mutation promotes greater aggregation and fibrillation in the LBs, and interferes with neurotransmission 9 , which confirms its role in the pathogenesis of the disease.
Therefore, this study aimed to analyse the frequency of the genetic variant SNCA-A53T in a Brazilian population with familial PD (FPD) or sporadic PD.
METHOD
A total of 294 individuals divided into two groups were studied: Study Group with 154 PD patients and Control Group formed by140 subjects, who had not been diagnosed with PD. The study group included PD patients older than 50 years, regardless of ethnicity 10 and sex. The patients were examined at the Outpatient Clinic for Movement Disorders of Hospital de Base, Medical School of São José do Rio Preto.
Diagnosis of PD followed the criteria recommended by Jankovic 11 , including bradykinesia, rigidity, resting tremor, postural instability, unilateral onset, L-dopa response for more than five years, levodopa-induced dyskinesia, progressive disorder, persistent asymmetry and clinical course of ten years or more, as well as complementary tests. The Control Group was selected in ambulatory clinics of that institution, namely, orthopedics, gynecology, among others. All subjects were informed about the study and confirmed their willingness to participate by signing an informed consent form. The study was approved by the Ethics Research Committee of institution.
The subjects were studied considering allele and genotypic frequencies for theSNCA-A53T mutation. Blood was collected by venepuncture with EDTA, and the genomic DNA was extracted from whole blood (5 mL) following the salting-out method 12 . PCR amplification of DNA was performed in a thermocycler (Eppendorf -Mastercycler). Each tube included 0.5 mL of each deoxynucleotide (0.8 mM); 2.5mLof10 X PCR buffer; 2.5mL of 10% dimethyl sulfoxide; 2.5mL of each primer (2.5mM); 0.2mL of Taq polymerase (5U/mL); 11 mL of Milli Q water; 2mL of genomic DNA dilution (0.2 mg). For the PCR, the following primer sequences were used: (exon 4): P1-5' GCT AAT CAG CAA TTT AAG GCT AG 3'; P2-5' GAT ATG TTC TTA GAT GCT CAG 3'. The initial DNA denaturation was achieved at 94ºC for 4 minutes. Next, the reaction mixture was subjected to 35 cycles of 94ºC for 20 seconds and of 55 ºC for 30 seconds, to an extension at 72°C for 45 seconds, and to a final cycle at 72°C for 10 minutes 13 . The post PCR product was digested with the restriction enzyme Tsp45I at 37°C for 4 hours and coloured by GelRed® (Uniscience). Electrophoresis was performed in 1% agarose gel at constant current of 100 V during 40 minutes, in order to separate fragments of 88pb, 128pb and 216pb in the presence of mutation (AG); 216pb for homozygous wild-type (GG) as well as 88pb and 128pb for homozygous mutant (AA). A sample of standard DNA (100bp Invitrogen) was used for comparison of the electrophoretic bands (Figure) . The quantitative and qualitative analysis was performed by t-test and Chi-square test, respectively, with the use of the MiniTab14 and GraphPad3 software. The adopted level of significance was p < 0.05.
RESULTS
Table shows demographic data and history of PD patients. The mean age was 67.9 ± 11.5 years in the study group, and 51.0 ± 20.4 years in the control group (p < 0.0001). The study included only those patients with disease duration longer than 10 years.
There was a prevalence of males in the study group (N = 95; 61.6%) compared with the control group (N = 55; 39.2%%; p = 0. 0002). In the study group, 37 patients (24.0%) showed history of familial PD versus 117 patients (75.9%) with sporadic PD.
Patients were qualified as familial, when they had at least one relative of first degree diagnosed with PD, regardless of Mendelian pattern of inheritance. Sporadic cases included individuals without any family history of the disease in the past three generations.
The genome analysis of all patients and controls showed homozygous wild-type genotype (GG), which demonstrates the absence of SNCA-A53T mutation in both groups.
DISCUSSION
This study has not found any association of A53T mutation in the SNCA gene with Parkinson's disease. This corroborates the data presented by Moura et al. 14 , who conducted research on Brazilian populations and quantified the SNCA gene mutations without finding any alterations. SNCA multiplications have been implicated in autosomal dominant forms of PD since 2003 15 . However, it became clear that whole-gene multiplications in SNCA locus are a rare form of parkinsonism and may account for only a small fraction of the total number of PD patients 16, 17 . Remarkably, further Brazilian studies found no SNCA-A53T mutation in PD patients 14, 18, 19 . Furthermore, other genes re1ated to PD, such as APOE, GSTs and LRRK2 (PARK8), also showed no difference between patients and controls in this population 20, 21, 22, 23 . On the other hand, mutations in the genes GIGYF (PARK11), ATP13A2 (PARK9) and GBA were associated with PD 6 . Vaughan et al. 13 evaluated 7 exons of SNCA gene in 30 European and American children with autosomal dominant PD, who did not show either A53T mutation or other mutations. Another study, also with PD patients, did not confirm the presence of this genetic variant in the SNCA gene 24 . Moreover, Athanassiadou et al. 25 assessed 19 families with no biological relations, where at least two relatives of first/second degree were affected with PD. The authors observed the presence of the mutation in several members of those 7 families, showing autosomal dominant inheritance pattern. Choi et al. 26 identified the A53T mutation in only 1 of 72 patients with early-onset PD, whose family history was consistent with autosomal dominant PD.
In this study, the selected population was of mixed ethnicity 10 , unlike the population in which the SNCA-A53T mutation was found 27 . Furthermore, in this study, control subjects, without a family history of PD, were selected from other speciality clinics, which made it difficult to perform matching pair analysis on sex and age with the group of patients. This may be a limitation of this study. Elderly individuals (> 60 years) have been treated in the several speciality clinics of the hospital and showed other neurodegenerative diseases, which were considered as exclusion criteria for this study.
However, these discrepancies seem to have little relevance, considering the absence of said mutation in both groups, which seems to be different in the Brazilian population 14, 18, 19 . Additionally, individuals remained in the control group, regardless of the matching pair analysis with patients, which enabled a larger number of individuals to perform comparative analysis.
Mutations in the SNCA gene enhance the production of alpha-synuclein protein, which contributes to the pathogenesis of PD 28 . SNCA is expressed throughout the brain, specially in presynaptic nerve terminals, and SNCA-A53T rather tends to form aggregates there are critical to Lewy bodies formation, both familial and idiopathic PD. This aggregation of SNCA is thought to be a key occurence in dopaminergic neuronal cell loss 3, 29 . The role of SNCA under normal physiological conditions is not yet completely clear, although there is evidence that implicates SNCA in neurotransmitter release and vesicle turnover at the presynaptic terminals 30 . However, this study conducted in a population of mixed ethnicity showed that both FPD and SPD are not associated with SNCA-A53T, which suggests the need for further evaluation and identification of larger and specific risk subgroups. Also, understanding the molecular mechanisms involved in its development will contribute to the application of molecular therapy interventions. 
